YMAB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 22.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $2,618,929.67

Y-mAbs Therapeutics Insider Trading History Chart

Y-mAbs Therapeutics Share Price & Price History

^$4.43

▼ -0.38 (-7.90%)

As of 03/31/2025 05:00 PM ET

Days: 30 | 90 | 365

Y-mAbs Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2025	Michael J Rossi	CEO	Sell	3,917	$5.20	$20,368.40	137,083
3/7/2025	Thomas Gad	Insider	Sell	10,810	$5.23	$56,536.30	202,721
9/16/2024	Thomas Gad	Insider	Sell	30,000	$12.97	$389,100.00	67,681
9/13/2024	Thomas Gad	Insider	Sell	65,000	$13.47	$875,550.00	97,681
8/26/2024	Joris Wilms	COO	Sell	5,000	$14.69	$73,450.00	30,600
6/10/2024	Gerard Ber	Director	Sell	722	$12.00	$8,664.00	1,608
6/10/2024	Thomas Gad	Insider	Sell	35,000	$12.03	$421,050.00	197,681
5/31/2024	Bo Kruse	CFO	Sell	31,371	$12.07	$378,647.97	210,877
5/23/2024	Thomas Gad	Insider	Sell	7,351	$13.00	$95,563.00	232,681
5/21/2024	Thomas Gad	Insider	Sell	25,000	$12.00	$300,000.00	240,032
3/5/2024	Vignesh Rajah	SVP	Sell	1,711	$16.53	$28,282.83	33,889
12/15/2023	Thomas Gad	Insider	Sell	50,000	$6.61	$330,500.00	265,032
12/13/2023	Thomas Gad	Insider	Sell	50,000	$6.58	$329,000.00	365,032
12/11/2023	Biotech Aps Wg	Director	Buy	102,863	$7.01	$721,069.63	4,552,778
12/7/2023	Biotech Aps Wg	Director	Buy	6,183	$6.50	$40,189.50	4,431,412
11/29/2023	Biotech Aps Wg	Director	Buy	51,837	$5.97	$309,466.89	4,425,229
11/27/2023	Johan Wedell-Wedellsborg	Director	Buy	62,516	$5.49	$343,212.84	4,342,721
11/20/2023	Thomas Gad	Insider	Sell	75,000	$5.30	$397,500.00	490,032
5/15/2023	Johan Wedell-Wedellsborg	Director	Buy	101,740	$9.65	$981,791.00	4,280,205
11/15/2022	Vignesh Rajah	CMO	Buy	1,195	$4.92	$5,879.40	4,266

See Full Table

SEC Filings (Institutional Ownership Changes) for Y-mAbs Therapeutics (NASDAQ:YMAB)

70.85% of Y-mAbs Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Y-mAbs Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/24/2025	Wellington Management Group LLP	133,263	$1.04M	0.0%	-2.5%	0.295%
2/26/2025	Infinitum Asset Management LLC	155,529	$1.22M	0.6%	N/A	0.347%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	52,356	$0.41M	0.0%	+17.4%	0.117%
2/17/2025	Soleus Capital Management L.P.	349,982	$2.74M	0.2%	-12.5%	0.781%
2/17/2025	Squarepoint Ops LLC	102,968	$0.81M	0.0%	-33.5%	0.230%
2/17/2025	Two Sigma Advisers LP	73,900	$0.58M	0.0%	-13.1%	0.165%
2/17/2025	Two Sigma Investments LP	88,337	$0.69M	0.0%	+31.6%	0.197%
2/17/2025	Rafferty Asset Management LLC	41,255	$0.32M	0.0%	+17.6%	0.092%
2/17/2025	ProShare Advisors LLC	12,645	$99K	0.0%	N/A	0.028%
2/17/2025	Paradigm Biocapital Advisors LP	4,236,346	$33.17M	1.2%	+3.7%	9.458%
2/17/2025	Millennium Management LLC	35,447	$0.28M	0.0%	-50.5%	0.079%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	22,818	$0.18M	0.0%	+12.6%	0.051%
2/17/2025	Deutsche Bank AG	32,253	$0.25M	0.0%	+52.2%	0.072%
2/17/2025	D. E. Shaw & Co. Inc.	615,131	$4.82M	0.0%	-21.9%	1.373%
2/17/2025	Cubist Systematic Strategies LLC	48,011	$0.38M	0.0%	N/A	0.107%
2/17/2025	Bridgeway Capital Management LLC	49,900	$0.39M	0.0%	-34.3%	0.111%
2/17/2025	Bank of America Corp DE	127,159	$1M	0.0%	+59.5%	0.284%
2/17/2025	BNP Paribas Financial Markets	4,874	$38K	0.0%	-81.6%	0.011%
2/17/2025	Acorn Capital Advisors LLC	2,861,825	$22.41M	12.3%	N/A	6.389%
2/14/2025	Caligan Partners LP	1,767,982	$13.84M	3.7%	+47.9%	3.947%
2/14/2025	Jane Street Group LLC	33,203	$0.26M	0.0%	-14.7%	0.074%
2/14/2025	Northern Trust Corp	359,223	$2.81M	0.0%	+6.5%	0.802%
2/14/2025	Boothbay Fund Management LLC	693,693	$5.43M	0.1%	+24.4%	1.549%
2/14/2025	Virtus ETF Advisers LLC	35,789	$0.28M	0.1%	+30.9%	0.080%
2/14/2025	Price T Rowe Associates Inc. MD	14,067	$0.11M	0.0%	-37.6%	0.031%
2/14/2025	Dimensional Fund Advisors LP	463,235	$3.63M	0.0%	-3.0%	1.034%
2/13/2025	Marshall Wace LLP	49,225	$0.39M	0.0%	+217.4%	0.110%
2/13/2025	Jump Financial LLC	33,380	$0.26M	0.0%	N/A	0.075%
2/13/2025	XTX Topco Ltd	20,768	$0.16M	0.0%	+83.8%	0.046%
2/13/2025	Barclays PLC	75,862	$0.59M	0.0%	+9.6%	0.169%
2/13/2025	Renaissance Technologies LLC	131,600	$1.03M	0.0%	+371.7%	0.294%
2/13/2025	Legal & General Group Plc	34,942	$0.27M	0.0%	-7.3%	0.078%
2/13/2025	Wells Fargo & Company MN	17,458	$0.14M	0.0%	+54.1%	0.039%
2/12/2025	ExodusPoint Capital Management LP	32,256	$0.25M	0.0%	N/A	0.072%
2/12/2025	Geode Capital Management LLC	822,309	$6.44M	0.0%	+1.1%	1.836%
2/12/2025	Wellington Management Group LLP	133,263	$1.04M	0.0%	-2.5%	0.298%
2/12/2025	Pictet Asset Management Holding SA	756,297	$5.92M	0.0%	+9.9%	1.689%
2/12/2025	JPMorgan Chase & Co.	97,660	$0.77M	0.0%	+221.9%	0.218%
2/11/2025	Prudential Financial Inc.	18,625	$0.15M	0.0%	-39.2%	0.042%
2/11/2025	Vanguard Group Inc.	2,000,022	$15.66M	0.0%	-1.7%	4.465%
2/11/2025	KLP Kapitalforvaltning AS	5,900	$46K	0.0%	N/A	0.013%
2/7/2025	AlphaQuest LLC	27,135	$0.21M	0.0%	+6,911.6%	0.061%
2/6/2025	Charles Schwab Investment Management Inc.	284,540	$2.23M	0.0%	+1.8%	0.635%
1/31/2025	Principal Financial Group Inc.	22,197	$0.17M	0.0%	+9.4%	0.050%
1/17/2025	SG Americas Securities LLC	17,729	$0.14M	0.0%	+30.7%	0.040%
12/26/2024	JPMorgan Chase & Co.	30,335	$0.40M	0.0%	+10.4%	0.068%
12/19/2024	Principal Financial Group Inc.	20,294	$0.27M	0.0%	N/A	0.045%
11/19/2024	Barclays PLC	69,222	$0.91M	0.0%	+433.4%	0.155%
11/18/2024	Empire Financial Management Company LLC	16,000	$0.21M	0.1%	N/A	0.036%
11/16/2024	Geode Capital Management LLC	813,489	$10.70M	0.0%	+6.2%	1.816%
11/15/2024	Barclays PLC	69,222	$0.91M	0.0%	+433.4%	0.155%
11/15/2024	XTX Topco Ltd	11,300	$0.15M	0.0%	-54.1%	0.025%
11/15/2024	Wellington Management Group LLP	136,714	$1.80M	0.0%	-14.8%	0.305%
11/15/2024	State Street Corp	1,209,781	$15.91M	0.0%	+50.4%	2.701%
11/15/2024	Point72 Asset Management L.P.	95,383	$1.25M	0.0%	-73.4%	0.213%
11/14/2024	Caligan Partners LP	1,195,253	$15.72M	5.0%	+105.3%	2.669%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	44,591	$0.59M	0.0%	-23.5%	0.100%
11/14/2024	Zurcher Kantonalbank Zurich Cantonalbank	3,324	$44K	0.0%	N/A	0.007%
11/13/2024	FMR LLC	36,416	$0.48M	0.0%	+23.1%	0.081%
11/12/2024	Charles Schwab Investment Management Inc.	279,577	$3.68M	0.0%	+9.4%	0.627%
11/9/2024	Intech Investment Management LLC	10,149	$0.13M	0.0%	N/A	0.023%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	94,225	$1.24M	0.0%	-46.5%	0.211%
10/31/2024	Principal Financial Group Inc.	20,294	$0.27M	0.0%	N/A	0.046%
10/28/2024	Rice Hall James & Associates LLC	108,684	$1.43M	0.1%	+21.1%	0.244%
10/25/2024	China Universal Asset Management Co. Ltd.	8,572	$0.11M	0.0%	+66.3%	0.020%
10/10/2024	Exchange Traded Concepts LLC	12,872	$0.17M	0.0%	-11.2%	0.029%
10/3/2024	SG Americas Securities LLC	13,566	$0.18M	0.0%	N/A	0.031%
9/16/2024	Cubist Systematic Strategies LLC	6,597	$80K	0.0%	-91.5%	0.015%
8/19/2024	Point72 Asset Management L.P.	358,945	$4.34M	0.0%	-76.5%	0.818%
8/15/2024	Millennium Management LLC	349,784	$4.23M	0.0%	+23.8%	0.797%
8/15/2024	AQR Capital Management LLC	21,926	$0.27M	0.0%	-42.1%	0.050%
8/14/2024	Squarepoint Ops LLC	126,389	$1.53M	0.0%	+143.4%	0.288%
8/14/2024	Cubist Systematic Strategies LLC	6,597	$80K	0.0%	-91.5%	0.015%
8/12/2024	XTX Topco Ltd	24,621	$0.30M	0.0%	N/A	0.056%
8/9/2024	Renaissance Technologies LLC	64,637	$0.78M	0.0%	-43.9%	0.147%
8/9/2024	Dimensional Fund Advisors LP	484,431	$5.85M	0.0%	+15.7%	1.104%
8/9/2024	Massachusetts Financial Services Co. MA	82,202	$0.99M	0.0%	+3.5%	0.187%
8/8/2024	Rice Hall James & Associates LLC	89,735	$1.08M	0.1%	+4.2%	0.204%
8/6/2024	Acadian Asset Management LLC	323,175	$3.90M	0.0%	-46.3%	0.736%
7/26/2024	Bank of New York Mellon Corp	120,954	$1.46M	0.0%	+8.0%	0.276%
5/28/2024	Boston Partners	34,165	$0.56M	0.0%	N/A	0.078%
5/16/2024	California State Teachers Retirement System	3,700	$60K	0.0%	-38.9%	0.008%
5/16/2024	Jacobs Levy Equity Management Inc.	154,016	$2.50M	0.0%	-39.1%	0.351%
5/16/2024	Caxton Associates LP	18,807	$0.31M	0.0%	N/A	0.043%
5/15/2024	Price T Rowe Associates Inc. MD	21,158	$0.35M	0.0%	+8.5%	0.048%
5/13/2024	Ameritas Investment Partners Inc.	3,701	$60K	0.0%	+39.9%	0.008%
5/10/2024	Acadian Asset Management LLC	602,314	$9.79M	0.0%	-24.9%	1.373%
5/10/2024	Vanguard Group Inc.	2,069,517	$33.65M	0.0%	-7.8%	4.717%
5/7/2024	SG Americas Securities LLC	11,963	$0.20M	0.0%	-44.5%	0.027%
4/29/2024	Principal Financial Group Inc.	13,729	$0.22M	0.0%	-7.4%	0.031%
4/29/2024	China Universal Asset Management Co. Ltd.	8,390	$0.14M	0.0%	+66.1%	0.019%
4/5/2024	Los Angeles Capital Management LLC	127,551	$2.07M	0.0%	-64.2%	0.291%
2/13/2024	Tower Research Capital LLC TRC	6,686	$46K	0.0%	+345.4%	0.015%
2/13/2024	Campbell & CO Investment Adviser LLC	82,391	$0.56M	0.1%	N/A	0.189%
2/9/2024	Trexquant Investment LP	28,616	$0.20M	0.0%	-62.6%	0.066%
2/8/2024	Massachusetts Financial Services Co. MA	79,617	$0.54M	0.0%	-3.1%	0.183%
2/6/2024	Sapient Capital LLC	43,700	$0.30M	0.0%	N/A	0.100%
2/6/2024	Los Angeles Capital Management LLC	356,530	$2.43M	0.0%	+17.3%	0.817%
2/6/2024	New York Life Investment Management LLC	68,932	$0.47M	0.0%	-2.9%	0.158%
2/5/2024	Russell Investments Group Ltd.	16,928	$0.12M	0.0%	-36.5%	0.039%

Data available starting January 2016

See Full Table

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $4.43

$4.37

$4.74

50 Day Range

MA: $5.58

$4.54

$6.42

52 Week Range

Now: $4.43

$4.25

$17.78

Volume

392,180 shs

Average Volume

334,040 shs

Market Capitalization

$200.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Who are the company insiders with the largest holdings of Y-mAbs Therapeutics?: Y-mAbs Therapeutics' top insider shareholders include:
Biotech Aps Wg (Director)
Johan Wedell-Wedellsborg (Director)
Thomas Gad (Insider)
Bo Kruse (CFO)
Michael J Rossi (CEO)
Vignesh Rajah (SVP)
Joris Wilms (COO)
Gerard Ber (Director)
Learn More about top insider investors at Y-mAbs Therapeutics.
Who are the major institutional investors of Y-mAbs Therapeutics?: Y-mAbs Therapeutics' top institutional shareholders include:
Paradigm Biocapital Advisors LP — 9.46%
Acorn Capital Advisors LLC — 6.39%
Vanguard Group Inc. — 4.47%
Caligan Partners LP — 3.95%
Geode Capital Management LLC — 1.84%
Pictet Asset Management Holding SA — 1.69%
Learn More about top institutional investors of Y-mAbs Therapeutics stock.
Which major investors are selling Y-mAbs Therapeutics stock?: During the previous quarter, YMAB stock was sold by these institutional investors:
D. E. Shaw & Co. Inc.
Squarepoint Ops LLC
Soleus Capital Management L.P.
Millennium Management LLC
Vanguard Group Inc.
Bridgeway Capital Management LLC
BNP Paribas Financial Markets
Dimensional Fund Advisors LP
During the previous year, company insiders that have sold Y-mAbs Therapeutics company stock include:
Biotech Aps Wg (Director)
Johan Wedell-Wedellsborg (Director)
Thomas Gad (Insider)
Bo Kruse (CFO)
Michael J Rossi (CEO)
Learn More investors selling Y-mAbs Therapeutics stock.
Which major investors are buying Y-mAbs Therapeutics stock?: Within the last quarter, YMAB stock was purchased by institutional investors including:
Acorn Capital Advisors LLC
Caligan Partners LP
Infinitum Asset Management LLC
Paradigm Biocapital Advisors LP
Boothbay Fund Management LLC
Renaissance Technologies LLC
Pictet Asset Management Holding SA
JPMorgan Chase & Co.
During the last year, these company insiders have bought Y-mAbs Therapeutics stock:
Biotech Aps Wg (Director)
Johan Wedell-Wedellsborg (Director)
Learn More investors buying Y-mAbs Therapeutics stock.